ESTRO 2024 - Abstract Book

S1716

Clinical - Lung

ESTRO 2024

were in cStage III, and 88 were in cStage IV. There were 107 adenocarcinomas and 33 non-adenocarcinomas, with the median BED10 of 53.7 Gy 10 .

Median OS (mOS) was 11.3 month (95% confidence interval, 7.9 – 14.4 months) in the overall cohort. Univariate analysis showed that preserved ECOG-PS, oligometastatic NSCLC, clinical stage I – III at diagnosis, adenocarcinoma, and high BED 10 were significantly associated with longer OS. There were no significant association between OS and other investigated factors. In the multivariate analysis, ECOG-PS 0 – 1 (14.9 months vs. 3.8 months; P < 0.001), adenocarcinoma (13.1 months vs. 5.1 months; P = 0.013), and oligometastatic NSCLC (27.1 months vs. 7.8 months; P < 0.001) were significantly associated with longer OS.

Conclusion:

In our institute, palliative radiotherapy for the patients with oligometastatic NSCLC showed longer OS than those with non-oligometastatic NSCLC.

Keywords: palliative radiotherapy, oligometastatic disease

2154

Mini-Oral

Radiation oncologist opinions and practice on cardiotoxicity in lung cancer: an international survey

Gerard M Walls 1 , Joshua D Mitchell 2 , Alexander R Lyon 3 , Mark Harbinson 4 , Gerard G Hanna 5

1 Queen's University Belfast, Patrick G Johnston Centre for Cancer Research, Belfast, United Kingdom. 2 Washington University in St Louis, Department of Cardio-Oncology, St Louis, USA. 3 Royal Brompton & Harefield hospitals, Department of Cardiology, London, United Kingdom. 4 Queen's University Belfast, Wellcome-Wolfson Centre for Experimental Medicine, Belfast, United Kingdom. 5 Queen's University Belfast, Patrick G Johnston Centre, Belfast, United Kingdom

Purpose/Objective:

Symptomatic radiation cardiotoxicity presents within months to few years in patients treated for locally advanced non-small cell lung cancer (NSCLC), affecting 15 – 29% patients and leading to reduced overall survival (1 – 4). With advanced radiotherapy technology and the advent of immunotherapy, overall outcomes have improved for NSCLC, and a greater focus on treatment-related toxicity is now warranted. As such, the discipline of cardio-oncology seeks to improve cardiovascular outcomes and overall survival of patients treated for cancer. A global cross-sectional analysis of radiation oncologists who treat lung cancer was conducted by the International Cardio-Oncology Society (ICOS) to establish the impact of recently published literature and guidelines on practice.

Material/Methods: